Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
74 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
2 Completed Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
3 Completed China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
4 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
5 Recruiting Intrathecal Rituximab in Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Nervous System Diseases
Interventions: Drug: Rituximab IT;   Drug: methylprednisolone IV;   Drug: Rituximab IV
6 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
7 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
8 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
9 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
10 Completed Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
11 Recruiting Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Dimethyl Fumarate;   Drug: Placebo Oral Capsule
12 Not yet recruiting Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Intervention: Drug: Hydroxychloroquine
13 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
14 Active, not recruiting Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Condition: Multiple Sclerosis
Intervention: Drug: BG00012 (DMF) (Tecfidera®.)
15 Active, not recruiting A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Placebo
16 Recruiting Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
Conditions: Primary Progressive Multiple Sclerosis;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: Andrographolides;   Drug: placebo
17 Recruiting A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Rituximab
18 Active, not recruiting A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Interventions: Drug: Fampridine;   Drug: Placebo
19 Recruiting Measuring Active Microglia in Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Intervention: Radiation: [C11]PK-1195 PET scan
20 Completed Tear Analysis in the Diagnosis of Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Intervention: Procedure: tears sampling

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.